EFFICACY AND SAFETY OF TRIAMCINOLONE ACETONIDE INJECTION IN SUPRACHOROIDAL SPACE IN SUBJECTS WITH DIABETIC MACULAR EDEMA
DOI:
https://doi.org/10.54112/bcsrj.v2023i1.290Keywords:
triamcinolone acetonide, optical coherence tomography, suprachoroidal space, Diabetic macular edemaAbstract
This study aimed to assess the effectiveness and safety of triamcinolone acetonide administered through
suprachoroidal space in subjects with diabetic macular edema. A prospective study was conducted in the Department
of Ophthalmology, Nishtar Hospital, Multan, from April 2022- April 2023. A total of 40 patients with diabetic macular
edema by optical coherence tomography were included in the study. During surgery, 4mg/100 µL triamcinolone
acetonide was injected. The patients were followed up for a week to evaluate post-injection adverse effects. In addition,
It was noted that the injection improved the VA significantly. After 6 months of follow-up, the VA was 0.69 ± 0.1
(p<0.001). Significant improvement was seen in optical coherence tomography measurement; after 6 months, it was
reduced to 265.6 ± 39.1 µm (p<0.001). No significant difference was noted in intraocular pressure from baseline to
follow-up. Based on the results, administering triamcinolone acetonide through suprachoroidal space in diabetic
macular edema is effective without any adverse effects.
Downloads
References
Ali, B. M., Azmeh, A. M., and Alhalabi, N. M. (2023). Suprachoroidal triamcinolone acetonide for the treatment of macular edema associated with retinal vein occlusion: a pilot study. BMC ophthalmology 23, 1-13.
Campochiaro, P. A., Wykoff, C. C., Brown, D. M., Boyer, D. S., Barakat, M., Taraborelli, D., Noronha, G., and Group, T. S. (2018). Suprachoroidal triamcinolone acetonide for retinal vein occlusion: results of the tanzanite study. Ophthalmology Retina 2, 320-328.
Emami-Naeini, P., and Yiu, G. (2019). Medical and surgical applications for the suprachoroidal space. International ophthalmology clinics 59, 195.
Eriş, E., Perente, I., Vural, E., Vural, A., Seymen, Z., Celebi, A. R. C., Erdogan, G., Ozkaya, A., and Artunay, O. (2019). Evaluation of the effect of combined intravitreal ranibizumab injection and sub-tenon steroid injection in the treatment of resistant diabetic macular edema. International ophthalmology 39, 1575-1580.
Hong, I. H., Choi, W., and Han, J. R. (2020). The effects of intravitreal triamcinolone acetonide in diabetic macular edema refractory to anti-VEGF treatment. Japanese Journal of Ophthalmology 64, 196-202.
Isaac, D. L. C., Abud, M. B., Frantz, K. A., Rassi, A. R., and Avila, M. (2012). Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double‐blind study. Acta ophthalmologica 90, 56-60.
Jorge, E. C., Jorge, E. N., Botelho, M., Farat, J. G., Virgili, G., and El Dib, R. (2018). Monotherapy laser photocoagulation for diabetic macular oedema. Cochrane Database of Systematic Reviews.
Kim, E. J., Lin, W. V., Rodriguez, S. M., Chen, A., Loya, A., and Weng, C. Y. (2019). Treatment of diabetic macular edema. Current diabetes reports 19, 1-10.
Naftali Ben Haim, L., and Moisseiev, E. (2021). Drug delivery via the suprachoroidal space for the treatment of retinal diseases. Pharmaceutics 13, 967.
Rittiphairoj, T., Mir, T. A., Li, T., and Virgili, G. (2020). Intravitreal steroids for macular edema in diabetes. Cochrane Database of Systematic Reviews.
Wykoff, C. C., Khurana, R. N., Lampen, S. I., Noronha, G., Brown, D. M., Ou, W. C., and Sadda, S. R. (2018). Suprachoroidal triamcinolone acetonide for diabetic macular edema: the HULK trial. Ophthalmology Retina 2, 874-877.
Yeh, S., Kurup, S. K., Wang, R. C., Foster, C. S., Noronha, G., Nguyen, Q. D., Do, D. V., and Team, D. S. (2019). Suprachoroidal injection of triamcinolone acetonide, CLS-TA, for macular edema due to noninfectious uveitis: a randomized, phase 2 study (DOGWOOD). Retina 39, 1880-1888.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 M FATIMA, S ABBAS, T SAJJAD
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.